November 29, 2012 9:18am EST
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK) today announced the award of research
grants from the Mexican National Technology and Science Council (Consejo
Nacional de Ciencia y Tecnología, CONACYT). The grants will be used by
Exakta-OPKO, OPKO's wholly-owned Mexican subsidiary, to advance
development of several research projects in ophthalmology, infectious
diseases, and oncology.
Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer,
commented, “We believe these grants, along with prior grants from
CONACYT, will facilitate research projects that could lead to
development of important diagnostic and therapeutic products for Mexico
and other countries.”
About OPKO Health, Inc.
We are a multi-national biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large and rapidly
growing medical markets by leveraging our discovery, development and
commercialization expertise and our novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding our product development efforts
and the ability of OPKO and Exakta-OPKO to develop important therapeutic
and diagnostic products for Mexico and Latin America, including products
for ophthalmology, infectious disease and oncology, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission, as
well as risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation,
among other factors. The forward-looking statements contained in this
press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin, 305-575-4100
or
Juan
Rodriguez, 305-575-4102
Source: OPKO Health, Inc.
Released November 29, 2012
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page